FDA lifts suspension of Juno clinical trial

The Food and Drug Administration is allowing Juno Therapeutics (Nasdaq: JUNO) to resume the clinical cancer treatment trial that the regulatory agency suspended last week after two patients died. The news marks a swift turnaround for Juno, which warned investors just on Thursday that the suspension would hamper the company’s efforts to get FDA approval by 2017 of its cancer therapy used in the trial. The trial, which involves hospitals across the U.S., is resuming with a revised protocol, under…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news

Related Links:

Authors: Reid E, Suneja G, Ambinder RF, Ard K, Baiocchi R, Barta SK, Carchman E, Cohen A, Gupta N, Johung KL, Klopp A, LaCasce AS, Lin C, Makarova-Rusher OV, Mehta A, Menon MP, Morgan D, Nathwani N, Noy A, Palella F, Ratner L, Rizza S, Rudek MA, Taylor J, Tomlinson B, Wang CJ, Dwyer MA, Freedman-Cass DA Abstract People living with HIV (PLWH) are diagnosed with cancer at an increased rate over the general population and generally have a higher mortality due to delayed diagnoses, advanced cancer stage, comorbidities, immunosuppression, and cancer treatment disparities. Lack of guidelines and provider education has le...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
ConclusionNone of the treatment methods applied ensured a full release of the restriction within the shoulder and upper limb. The deficits observed may constitute a serious disorder of the musculoskeletal system; therefore, a clinical study of biomechanical parameters of the shoulder joint may be an important control of patients’ functional status after breast cancer treatment.
Source: Reports of Practical Oncology and Radiotherapy - Category: Cancer & Oncology Source Type: research
Publication date: Available online 13 August 2018Source: Radiation Physics and ChemistryAuthor(s): Ali Asghar Borran, Ayoub Aghanejad, Alireza Farajollahi, Jaleh Barar, Yadollah OmidiAbstractRadiation therapy is a regular treatment modality for the cancer therapy. Despite being a beneficial strategy, the radiation doses are limited, in large part because of the occurrence of inadvertent toxicity in the surrounding healthy tissues/organs. Among efforts to minimize the unwanted side effects in normal tissues and sensitize tumor tissues/organs to radiation, utilization of the high atomic number material such as noble metals (...
Source: Radiation Physics and Chemistry - Category: Physics Source Type: research
Cytokine-based cancer therapies have attracted a great deal of attention in recent years. Unfortunately, resistance to treatment limits the efficacy of these therapeutics. Therefore, the aim of our study was t...
Source: Cancer Cell International - Category: Cancer & Oncology Authors: Tags: Primary research Source Type: research
ConclusionsIn conclusion, we demonstrate that Oncologist-led rapid access clinics are successful concepts to assess patients with unexplained lymphadenopathy. Our data suggest that a routine use of FNA should be reconsidered in this setting.
Source: BMC Hematology - Category: Hematology Source Type: research
Barbara Wegiel, Marta Vuerich, Saeed Daneshmandi, Pankaj Seth
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionLower levels of antioxidant enzymes and non-enzymatic small molecules and higher levels of oxidative stress and inflammatory clinical parameters such as NO, MDA, TNF-α and MMP-9 may be involved in the pathogenesis of systemic chemotherapy related ocular complications such as cataract, glaucoma, blepharitis, retinitis pigmentosa, macular degeneration, pterygium and retinal degeneration etc.
Source: Saudi Journal of Biological Sciences - Category: Biology Source Type: research
Publication date: Available online 10 August 2018Source: Diabetes &Metabolic Syndrome: Clinical Research &ReviewsAuthor(s): Ala'a G. Almagthali, Eman H. Alkhaldi, Afnan S. Alzahrani, Ameera K. Alghamdi, Waleed Y. Alghamdi, Ahmed M. KabelAbstractDipeptidyl peptidase (DPP- 4) inhibitors belong to the oral antidiabetic drugs. They are used for the treatment of Type 2 Diabetes mellitus. DPP-4 is an enzyme which puts down the action of hormone, incretin. Incretins belong to the group of hypoglycaemic gastrointestinal hormones. Some studies show that DPP-4 inhibitors causes cancer and some study show that they have antic...
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research
This study demonstrated 77 protein features that were significantly changed in protein expression and revealed evodiamine-induced cytotoxicity in thyroid cancer cells involves dysregulation of protein folding, cytoskeleton, cytoskeleton regulation and transcription control. Our work shows that this combined proteomic strategy provides a rapid method to study the molecular mechanisms of evodiamine-induced cytotoxicity in thyroid cancer cells. The identified targets may be useful for further evaluation as potential targets in thyroid cancer therapy.Graphical abstract
Source: Journal of Pharmaceutical and Biomedical Analysis - Category: Drugs & Pharmacology Source Type: research
Purpose of review Targeting cancer metabolism for therapy has received much attention over the last decade with various small molecule inhibitors entering clinical trials. The present review highlights the latest strategies to target glucose and glutamine metabolism for cancer therapy with a particular emphasis on novel combinatorial treatment approaches. Recent findings Inhibitors of glucose, lactate, and glutamine transport and the ensuing metabolism are in preclinical to clinical trial stages of investigation. Recent advances in our understanding of cell-intrinsic and cell-extrinsic factors that dictate dependence ...
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: INNOVATIVE AGENTS AND TREATMENT MODALITIES: Edited by Ahmad Awada and Steven T. Rosen Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Clinical Trials | Food and Drug Administration (FDA) | Health | Health Management | Hospitals | Pharmaceuticals